Aclarion, Inc. (ACONW) Stock Price & Analysis
Aclarion, Inc. (ACONW) — price $0.0214 (0.00%), as of the Nov 19, 2026 trading session.
Educational signal · not a buy or sell recommendation · How to read this
Aclarion, Inc. · ACONW
Aclarion, Inc. is a healthcare technology company developing software for magnetic resonance spectroscopy (MRS) to provide objective diagnostics for lower back pain. Its NOCISCAN-LS suite calculates degenerative pain biomarkers, addressing a significant unmet need in spinal pain assessment.
Price as of Nov 19, 2026
Key Statistics
Not scored: this is a debt/preferred or other non-common instrument, or its reported market value does not match its share basis.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.0214 | |
| Change on the day | 0.00% | |
| 52-week range | $0.02 – $0.199 | |
| Shares traded on the day | 65.5K |
Price & events
What is Aclarion (ACONW), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Aclarion, Inc. (ACONW) is the company analyzed here. It employs 11 people and is led by Brent Ness. In Q3 FY2026 it reported revenue of $33,733 and net income of -$3M.
What do the latest results show for Aclarion (ACONW)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of $33,733. Against analyst estimates the company has EPS beat 2 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | $33,733 | -$3M | -$0.94 (diluted) |
| Q2 FY2026 | $25,208 | -$3M | -$1.12 (diluted) |
| Q1 FY2026 | $21,140 | -$3M | -$1.34 (diluted) |
| Q4 FY2025 | $18,479 | -$2M | -$2.21 (diluted) |
What are the financial strengths and risks for Aclarion (ACONW)?
Short answer · as of
The distress and quality screens read Altman Z -6.45 · Piotroski F 2. Trailing ratios: ROE -62.9% · ROA -63.9% · current ratio 14.17.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -6.45 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-62.9%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 3 of the last 8 reported quarters.
The records behind this page
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Aug 17, 2026
- Transactions
- 15
- Identified insiders
- 10
- Purchases
- 6
- Sales
- 0
- Other transactions
- 9
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ACONW in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported ACONW in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Aclarion (ACONW)?
- Aclarion Broadens CLARITY Trial Enrollment Criteria to Accelerate Enrollment
- Aclarion Announces Nociscan® Now Available at Goodman Campbell Brain & Spine at Ascension St. Vincent, First Site in Indiana to Offer the Technology
- Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform
Common Questions About ACONW
These answers are editorial: 1 of these 1 answer is drawn from the ACONW research dossier (written Jun 15, 2026 by gemini-2.5-flash). Figures in this section are not part of the source register.
What does Aclarion, Inc. do?
Aclarion, Inc. is a healthcare technology company that develops specialized software applications for magnetic resonance spectroscopy (MRS) in the United States.
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 14 figures on this page — 8 from Financial Modeling Prep (FMP) and 6 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com